Drug Development
18 articles RSS
Japan Grants Conditional Approval to the World's First iPS Cell Therapies for Parkinson's Disease and Heart Failure
Japan's health ministry has conditionally approved two iPS cell-derived drugs, marking the first time regenerative medicines built from induced pluripotent stem cells will reach patients commercially.
Roche's Amylin-Based Weight Loss Drug Delivers 10.7% Reduction in Phase 2 but Falls Short of Eli Lilly's Rival, Sending Zealand Pharma Shares Down 32%
Petrelintide met its primary endpoint with placebo-like tolerability, but a dose ceiling and a seven-point efficacy gap to Lilly's eloralintide raise questions about its standalone future.
Gilead's Single-Tablet HIV Regimen Matches Complex Multi-Pill Therapies in Two Phase 3 Trials, Lancet Reports
Two Phase 3 ARTISTRY trials show bictegravir/lenacapavir maintains viral suppression while replacing regimens of up to 11 daily pills with one tablet.
Keytruda Becomes First Immunotherapy to Extend Survival in Platinum-Resistant Ovarian Cancer
FDA approves pembrolizumab for a subset of ovarian cancer patients after Phase 3 KEYNOTE-B96 trial shows the first overall survival benefit ever demonstrated by an immunotherapy in this setting.
Merck's Once-Daily Cholesterol Pill Matches Injectable Efficacy in Phase 3 Trial, Opening Path to First Oral PCSK9 Inhibitor
Enlicitide decanoate cut LDL cholesterol by 57% in 2,900+ patients in the CORALreef Lipids Phase 3 trial — matching injectable PCSK9 inhibitors in pill form, with no meaningful safety signals over 52 weeks.
Scientists Identify the Enzyme That Shatters Chromosomes in One in Four Cancers, Revealing a New Target for Drug Resistance
UC San Diego researchers identify N4BP2 as the molecular trigger behind chromothripsis, the catastrophic chromosome-shattering event that drives treatment resistance in roughly a quarter of human cancers.